Synergistic effects of dexamethasone and rituximab
| Cell line . | Synergistic growth inhibition . | % annexin V+cells . | Supra-additive sub-G1 DNA . | Supra-additive G1 arrest . |
|---|---|---|---|---|
| DHL-4 | 21 | 38* | Yes | Yes |
| Daudi | 13 | 25* | Yes | No |
| FL-18 | −2 | 34 | No | No |
| Granta 519 | 7 | 9 | No | Yes |
| NCEB-1 | 10 | 14* | No | Yes |
| OCI Ly8 | 31 | 8 | No | No |
| Raji | 25 | 7 | No | No |
| Ramos | 2 | 14* | No | No |
| Tab | 14 | 57* | Yes | Yes |
| Cell line . | Synergistic growth inhibition . | % annexin V+cells . | Supra-additive sub-G1 DNA . | Supra-additive G1 arrest . |
|---|---|---|---|---|
| DHL-4 | 21 | 38* | Yes | Yes |
| Daudi | 13 | 25* | Yes | No |
| FL-18 | −2 | 34 | No | No |
| Granta 519 | 7 | 9 | No | Yes |
| NCEB-1 | 10 | 14* | No | Yes |
| OCI Ly8 | 31 | 8 | No | No |
| Raji | 25 | 7 | No | No |
| Ramos | 2 | 14* | No | No |
| Tab | 14 | 57* | Yes | Yes |
Synergistic growth inhibition is shown in the first column. The percentage increase in the growth inhibition is calculated as cpm/control (dexamethasone)—cpm/control (combination dexamethasone and rituximab). The higher the percentage, the greater the synergistic effect. Column 2 shows the mean percentage of early apoptotic cells that become annexin V+ (minus control) following treatment with 10 μg rituximab and 10 μM dexamethasone for 48 hours. This is the mean of 3 or more experiments. The asterisk indicates that supra-additive early apoptosis occurs in 5 cell lines. Column 3 shows supra-additive DNA fragmentation that is observed in 3 malignant B-cell lines following treatment with combined dexamethasone and rituximab. Column 4 shows that supra-additive G1 arrest is observed in 4 malignant B-cell lines.